Comparison of Postoperative Adjuvant Chemotherapy With/Without Rh-endostatin on Non-small Cell Lung Cancer in PhaseⅠB

Inclusion Criteria:

* Patients who are diagnosed with NSCLC pathologically and T stage is T2a in postoperative pathological staging. No lymph node and distant metastasis are observed and the surgical methods include wedge incision, segmentectomy of right lung or lobe.
* Age: 18～70 years
* ECOG PS score: 0-1 score
* patients who are diagnosed with the high risk factors as follows: poor differentiation (including low differentiation, undifferentiation and neuro-endocrine differentiation), blood vessel invasion, wedge incision, tumor diameter \>4 cm, visceral pleura involvement, incomplete clear of lymph node and incisal edge \<1.0 cm.
* Patients who are diagnosed without tumor recurrence before adjuvant chemotherapy.
* Informed consent is signed.

Exclusion Criteria:

* Patients with unexpected pathological patterns or those have received new adjuvant chemotherapy.
* Patients with other active malignant tumor history beside NSCLC before treatment except non-melanoma skin cancer, primary cervical cancer and cured early prostate cancer.
* Patients who are with chemotherapeutic contraindications, such as white blood count \<4.0×109/L, blood platelet count \<80×109/L or severe anemia (Hb\<80 g/L); obvious liver dysfunction (increased transaminase or bilirubin \>2.5 folds of normal level); un-manageable hypertension, diabetes, arrhythmia, repeated heart failure and chronic obstructive pulmonary diseases that could influence ventilation function; active stage of diseases infected by bacteria, fungi and virus; or patients who are in pregnancy and lactation periods.
* Patients who are un-recovered and poor with chemotherapy after 8-week treatment, or have received above 8-week treatment before treatment.
* Patients who are in poor obedience or other improper symptoms.